Shanthu Shantaram joins ABLE
Dr Shanthu Shantaram has been appointed as executive
director of the Association of Biotech Led Enterprises (ABLE), India.
He would take care of Special Interest Group on Agri-Biotechnology and
would be based in New Delhi.
An eminent agri-expert and an advocate of GM crops in India, Dr
Shantaram has been working as an independent consultant on
biotechnology and biosafety and environmental risk assessment of GM
crops with his own consulting firm, Biologistics International.
Earlier he worked as a senior research scholar of science, technology
and environmental policy at Princeton University and also with Syngenta
as a head of stakeholder relations and technology communications and
then as a global head of regulatory compliance.
Swati Piramal receives Global Empowerment Award
Dr Swati Piramal has received a special award at the
Eleventh Asian Women of Achievement Awards in London on May 19, 2010.
The Global Empowerment Award, which honors individuals whose vision
inspires economic and social progress across the world, was presented
by HRH Princess Michael of Kent and Amanda Mackenzie the chief
marketing officer of Aviva.
In 2009, Dr Piramal became the first woman in the 90-year history of
the Indian Chambers of Commerce, ASSOCHAM, to be elected president and
she immediately chose 100 women to chair the chamber’s national
In 1998, she co-founded fledgling company Nicholas Laboratories, which
has now grown into life sciences and healthcare multinational Piramal
Group. With operations in India, the US and Europe, the company employs
10,000 people and sells products to over 100 countries. Her focus on
‘democratizing’ healthcare in India led her to set up a national
She has also been the driving force behind many more medical
initiatives in India. In 1983, she founded the Gopikrishna Piramal
Memorial Hospital for underprivileged families with physically
handicapped children and has written hundreds of papers on drugs
pricing control, biotechnology regulation and data protection.
In 2006, she received the Chevalier de l’Ordre National du Merite
(Knight of the Order of Merit) from the French President Jacques Chirac
after being nominated by Forbes magazine as one of the 25 most powerful
women in India.
SRC appoints Dr
Bopanna as president
Semler Research Center (SRC), a subsidiary of Semler Group, has
appointed Dr Krathish Bopanna as president and executive director. In
this role, Dr Bopanna is responsible for the overall performance of SRC
in India and the US across its diverse business segments.
Prior to joining SRC, Dr Bopanna was with Manipal Acunova as the senior
vice president of Clinical Development. With over 15 years of
pharmaceutical experience, he has served leading positions in companies
like AstraZeneca and Tata Consulting Services.
Dr Abhijit Barve
is COO of Clinigene
Biocon‘s clinical research arm Clinigene, announced the appointment of
Dr Abhijit Barve as its chief operating officer (COO) with effect from
May 1, 2010.
Abhijit has over 15 years of global drug development experience
covering preclinical, early and late stage clinical development,
clinical operations, regulatory and safety functions. During this
timeframe, he has filed at least a dozen IND applications and has led
the team that successfully negotiated the original and expanded
labeling for Vaprisol.
“We are delighted to welcome Abhijit to Biocon and we are confident
that his global business and operational experience will add great
value to Clinigene’s ever evolving advancement in clinical development
programs,” said Dr Kiran Mazumdar-Shaw, CMD, Biocon.
Gupta to lead Strides’ pharma business
es Arcolab has appointed Manish Gupta as chief executive
officer of its pharma business. The appointment follows the
restructuring announced by the company in 2009 and the realignment of
its business along three verticals – pharma, specialty and branded
generics. With over 17 years of experience in leading and managing
business and performance enhancement across the US, Europe and India,
Gupta will be responsible for building and growing Strides Arcolab’s
Pharma business globally.
He began his career with AF Ferguson and moved to Khandwala Securities
before joining Wockhardt in 1998. His last position at the Wockhardt
Group was as managing director. In his 12-year stint at Wockhardt, he
handled 13 transactions (including five divestments) in the US, Europe
Shobana becomes CFO of TAKE Solutions
TAKE Solutions has appointed Shobana NS as the chief financial officer
(CFO). She has over 15 years of expertise in strategic and operational
aspects of management with continuous exposure and experience in supply
chain management and general management roles. She began her journey
with TAKE Solutions since its incorporation in 2000 and has been
instrumental in the development of the organization. In this period of
10 years, she showcased her proficiency in both strategic and
operational role and was vice president of finance and accounts before
being promoted to her new role.
appoints Dr John Ellingboe as senior VP
Hyderabad-based leading CRO GVK Biosciences (GVK BIO) has appointed Dr
John Ellingboe as senior vice president of Discovery Chemistry. He will
report to Manni Kantipudi, president of GVK BIO.
Prior to joining GVK BIO, Dr Ellingboe worked with Wyeth Research and
Pfizer for 25 years in senior scientific positions and has extensive
background in medicinal chemistry and drug discovery.
While at Wyeth, he initiated and managed a large chemistry partnership
with GVK BIO. He received his undergraduate degree in chemistry from
Reed College and a PhD in Organic Chemistry from MIT. He has over 150
publications, presentations and patents to his credit.